XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.
The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.
XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.
Business Strategy & Milestones for 2021
On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”
In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:
- Commercialization of infectious disease diagnostics
- Clinical validation of transdermal and sublingual drug formulations
- Continued investment and development in psychedelic medicine
“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”
Infectious Disease Diagnostics
XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.
Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.
In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.
XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
Drug Formulation & Delivery
In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.
XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:
- Rotigotine transdermal patch for Parkinson’s disease
- CBD oral/sublingual strip for treatment resistant epilepsy
- THC oral/sublingual strip for anorexia/nausea
- CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity
Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”
Psychedelic Medicine
Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:
- An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
- An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others
XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.
Management Team
Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.
Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.
Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.
Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.
Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.
Investment Considerations
- XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities.
- The company has research and development operations in North America and Europe and an operational focus in Germany.
- XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicine.
- The company’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system being evaluated in Europe for the detection of COVID-19.
- XPhyto’s German subsidiary, Vektor Pharma TF GmbH, is advancing four therapeutic programs targeting neurological indications; the company intends to complete human pilot studies evaluating these products in 2021.
- The company has two agreements in place focused on psychedelic compounds, a promising new class of API with strong potential for the treatment of mental health conditions.
TraderPower Featured Companies
- AzurRx BioPharma Inc. (NASDAQ: AZRX)
- Brain Scientific Inc. (OTCQB: BRSF)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Cybin Inc. (NEO: CYBN)
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)
- Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)
- Hollywall Entertainment Inc. (OTC: HWAL)
- Mohawk Group Holdings Inc. (NASDAQ: MWK)
- Knightscope, Inc.
- Net Element, Inc. (NASDAQ: NETE)
- Predictive Oncology (NASDAQ: POAI)
- Pressure BioSciences Inc. (PBIO)
- SRAX Inc. (NASDAQ: SRAX)
- TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)
- The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER)
- Uranium Energy Corp. (NYSE American: UEC)
- VistaGen Therapeutics Inc. (NASDAQ: VTGN)
- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)
Top Small Cap Market News
- $POAI Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients
- $UUUU Poised for Growth as Uranium Price Expected to Increase
- $IDEX Listed Among 4 Hot EV Stocks To Watch In March 2021 by PennyStocks.com
- $KAVL Adds Two New Distribution Partners, Additional Opportunity for Revenue Growth
- $PLTXF Announces Results of Annual and Special Meeting
- $SRAX Subsidiary LD Micro Regenerates Company Index to Reveal 423 New Players in MicroCap Space
- $TOBAF Enters into MOU with BC Life Sciences Firm
- $TOBAF Announces Online Site Racks Up CDN$100,000 Sales After Only Five Days, Adds New Taste Explorer Option
- $WTER 420 with CNW – What Five Major Studies Say About Cannabis and Your Sex Life
- $XPHYF Vermont Legislators Draft Drug, Psychedelic Decriminalization Bills for 2021 Session
- $XPHYF Releases Update on Promotional and Marketing Activity Comments
- $AMST to Focus on Whole Enterprise Solutions After Successful Platform Implementation
- $AMST Announces It Will Focus on Whole Enterprise Solutions After Successful Implementation of Its SaaS Ed-Tech Platform for The Henry Ford Museum of American Innovation
- $DRIO Hosting Conference Call to Release Q4, Full-Year Results
- $FRSX Issues Shareholder Letter, Announces Successful Completion of Eye-Net Trial
- $GNPX Announces Participation Schedule for March Investor Conferences
- $STLHF Announces Successfully Production of Battery Quality Lithium Carbonate Using OEM Technology
Recent Posts
- $STLHF Announces Successfully Production of Battery Quality Lithium Carbonate Using OEM Technology
- $GNPX Announces Participation Schedule for March Investor Conferences
- $FRSX Issues Shareholder Letter, Announces Successful Completion of Eye-Net Trial
- $DRIO Hosting Conference Call to Release Q4, Full-Year Results
- $AMST Announces It Will Focus on Whole Enterprise Solutions After Successful Implementation of Its SaaS Ed-Tech Platform for The Henry Ford Museum of American Innovation
- $AMST to Focus on Whole Enterprise Solutions After Successful Platform Implementation
- $XPHYF Releases Update on Promotional and Marketing Activity Comments
- $XPHYF Vermont Legislators Draft Drug, Psychedelic Decriminalization Bills for 2021 Session
Recent Comments
Archives
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009